Breast Cancer Clinical Trial

Genetic Testing for Breast, Ovarian, Pancreatic, and Prostate Cancers

Summary

This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

View Full Description

Full Description

This prospective, randomized controlled trial will evaluate the effect of two pre-test education methods on the level of participation in genetic testing for hereditary cancer risk. A prospective study examines outcomes before the development of a disease.

The research study procedures include screening for eligibility, randomization and a series of questionnaires.
Participants will be randomized, or assigned by chance, to one of two methods of pre-genetic test education and after completing either pre-test education participants will be offered the opportunity to have genetic testing performed

Two methods of pre-genetic test education:

video education
in-person counseling
Genetic testing will be performed by blood draw.
It is expected that 500 people will participate in this study
Participants will be in the research study for up to 5 yrs after enrollment

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Potentially eligible participants will be identified via medical record screening and/or in accordance with their clinical visit. A HIPAA waiver of authorization will be obtained by the enrolling Institution as needed to have access to the subject's medical record information for screening of eligibility.
A member of the study team will approach the potentially eligible participant in clinic and discuss the trial. Potentially eligible participants may choose to discuss participation further with their physician at their appointment
Age ≥ 18 years
Breast, ovarian, pancreatic, or metastatic prostate cancer
No prior cancer genetic testing
Ability to understand and the willingness to sign an informed consent document

Exclusion Criteria:

Pregnant
Prisoners
Inability to understand English as a spoken language in a healthcare context
Known hematologic malignancy (e.g. CLL)

Study is for people with:

Breast Cancer

Estimated Enrollment:

269

Study ID:

NCT04330716

Recruitment Status:

Completed

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States
Dana-Farber Cancer Institute at St. Elizabeth's Medical Center
Brighton Massachusetts, 02135, United States
Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center
Milford Massachusetts, 01757, United States
Dana-Farber/Brigham and Women's Cancer Center in clinical affiliation with South Shore Hospital
Weymouth Massachusetts, 02190, United States
Dana-Farber/New Hampshire Oncology-Hematology
Londonderry New Hampshire, 03053, United States
Lifespan Cancer Institute at Rhode Island Hospital
Providence Rhode Island, 02903, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

269

Study ID:

NCT04330716

Recruitment Status:

Completed

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.